I believe a significant number of patients that were “excluded” due to progression during that time were placed in an “information arm” of the trial, given DCVAX-L, and followed.
Wow it is a good paper overall that is 100% devoted to critically evaluating our DcVaxL phase 3 trial. Thanks for the German endorsement!!!!!!!!!!!!!!!